Duo Oncology
2 known investors
Duo Oncology develops tumor-activated prodrug combinations designed to replace multi-agent chemotherapy with single medicines that concentrate therapeutic activity in tumors. The company is advancing DUO-207, a clinical-stage prodrug combining gemcitabine and paclitaxel for solid-tumor cancer treatment.
BiotechMedical Devices
Investors · 2
In the news
- Fighting Cancer: Pitt Startup Duo Oncology Prepares for Nanomedicine Clinical Trialsinnovation.pitt.edu · 2025
- Pittsburgh Money Moves: Astrobotic won a NASA grant, Duo Oncology raised $3M and moretechnical.ly · 2023
- Duo Oncology raises $3M in seed round, here's what's next - Pittsburgh Business Timesbizjournals.com · 2023
- Duo Oncology Closes $3M Series Seed — Duo Oncologyduooncology.com · 2023
- Duo Oncology - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Duo Oncology - 2025 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021